KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Research & Development (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Research & Development for 15 consecutive years, with $27.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 2.86% to $27.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $106.2 million, a 2.35% decrease, with the full-year FY2025 number at $106.2 million, down 2.35% from a year prior.
  • Research & Development was $27.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $29.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $29.4 million in Q3 2025 to a low of $15.0 million in Q1 2021.
  • A 5-year average of $22.6 million and a median of $22.4 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 30.53% in 2021, then soared 48.79% in 2023.
  • Supernus Pharmaceuticals' Research & Development stood at $21.1 million in 2021, then decreased by 15.68% to $17.8 million in 2022, then surged by 31.35% to $23.3 million in 2023, then increased by 22.7% to $28.6 million in 2024, then fell by 2.86% to $27.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Research & Development are $27.8 million (Q4 2025), $29.4 million (Q3 2025), and $22.1 million (Q2 2025).